Stone Crest Wealth Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Stone Crest Wealth Management, Inc.
- $137 Billion
- Q3 2024
A detailed history of Stone Crest Wealth Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Stone Crest Wealth Management, Inc. holds 27,593 shares of VRDN stock, worth $595,181. This represents 0.46% of its overall portfolio holdings.
Number of Shares
27,593
Previous 27,484
0.4%
Holding current value
$595,181
Previous $358 Million
75.56%
% of portfolio
0.46%
Previous 0.27%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
151Shares Held
61.9MCall Options Held
133KPut Options Held
207K-
Black Rock Inc. New York, NY4.77MShares$103 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$84.6 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$83.7 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$72.2 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.31MShares$71.4 Million0.85% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $860M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...